To include your compound in the COVID-19 Resource Center, submit it here.
QRxPharma completed enrollment of 375 patients in the double-blind, U.S. Phase III Study 022
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury